AUROBINDO PHARMA 2018-19 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets will remain closed on 14th April, 2021 on account of Dr. Baba Saheb Ambedkar Jayanti.

AUROBINDO PHARMA 2018-19 Annual Report Analysis
Wed, 6 Nov

AUROBINDO PHARMA has announced its results for the year ended March 2019. Let us have a look at the detailed performance review of the company during FY18-19.

AUROBINDO PHARMA Income Statement Analysis

  • Operating income during the year rose 18.6% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 4.8% YoY during the fiscal. Operating profit margins witnessed a fall and stood at 20.2% in FY19 as against 22.9% in FY18.
  • Depreciation charges increased by 19.7% and finance costs increased by 237.9% YoY, respectively.
  • Other income grew by 52.3% YoY.
  • Net profit for the year declined by 2.4% YoY.
  • Net profit margins during the year declined from 14.6% in FY18 to 12.0% in FY19.

AUROBINDO PHARMA Income Statement 2018-19

No. of Mths Year Ending 12 Mar-18* 12 Mar-19* % Change
Net Sales Rs m 164,998 195,636 18.6%
Other income Rs m 1,020 1,553 52.3%
Total Revenues Rs m 166,018 197,189 18.8%
Gross profit Rs m 37,718 39,519 4.8%
Depreciation Rs m 5,580 6,680 19.7%
Interest Rs m 777 2,626 237.9%
Profit before tax Rs m 32,380 31,767 -1.9%
Tax Rs m 8,183 7,269 -11.2%
Profit after tax Rs m 24,229 23,645 -2.4%
Gross profit margin % 22.9 20.2
Effective tax rate % 25.3 22.9
Net profit margin % 14.6 12.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



India's Revival: A Once-in-a-Generation Wealth Making Opportunity

AUROBINDO PHARMA Balance Sheet Analysis

  • The company's current liabilities during FY19 stood at Rs 120 billion as compared to Rs 87 billion in FY18, thereby witnessing an increase of 39.0%.
  • Long-term debt down at Rs 2 billion as compared to Rs 5 billion during FY18, a fall of 60.1%.
  • Current assets rose 26% and stood at Rs 154 billion, while fixed assets rose 25% and stood at Rs 104 billion in FY19.
  • Overall, the total assets and liabilities for FY19 stood at Rs 265 billion as against Rs 211 billion during FY18, thereby witnessing a growth of 25%.

AUROBINDO PHARMA Balance Sheet as on March 2019

No. of Mths Year Ending 12 Mar-18* 12 Mar-19* % Change
Networth Rs m 116,804 138,908 18.9
 
Current Liabilities Rs m 86,659 120,429 39.0
Long-term Debt Rs m 4,512 1,800 -60.1
Total Liabilities Rs m 211,052 264,544 25.3
 
Current assets Rs m 121,878 153,645 26.1
Fixed Assets Rs m 83,345 103,909 24.7
Total Assets Rs m 211,052 264,544 25.3
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



AUROBINDO PHARMA Cash Flow Statement Analysis

  • AUROBINDO PHARMA's cash flow from operating activities (CFO) during FY19 stood at Rs 16 billion on a YoY basis.
  • Cash flow from investing activities (CFI) during FY19 stood at Rs -29 billion, an improvement of 49.3% on a YoY basis.
  • Cash flow from financial activities (CFF) during FY19 stood at Rs 19 billion, an improvement of 122% on a YoY basis.
  • Overall, net cash flows for the company during FY19 stood at Rs 7 billion from the Rs 9 billion net cash flows seen during FY18.

AUROBINDO PHARMA Cash Flow Statement 2018-19

Particulars No. of months 12 12 % Change
Year Ending Mar-18 Mar-19
Cash Flow from Operating Activities Rs m 19,545 16,220 -17.0%
Cash Flow from Investing Activities Rs m -19,266 -28,768 -
Cash Flow from Financing Activities Rs m 8,642 19,191 122.1%
Net Cash Flow Rs m 8,919 6,656 -25.4%
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Current Valuations for AUROBINDO PHARMA

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 40.4, an decline from the EPS of Rs 41.4 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 454.5, stands at 10.5 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 2.9 times, while the price to sales ratio stands at 2.0 times.
  • The company's price to cash flow (P/CF) ratio stood at 8.8 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-18* 12 Mar-19*
Sales per share (Unadj.) Rs 281.6 333.9
TTM Earnings per share Rs 41.4 40.4
Diluted earnings per share Rs 41.4 40.4
Price to Cash Flow x 8.9 8.8
TTM P/E ratio x 10.5 10.5
Price / Book Value ratio x 3.3 2.9
Market Cap Rs m 266,282 265,959
Dividends per share (Unadj.) Rs 2.5 2.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Ratio Analysis for AUROBINDO PHARMA

  • Solvency Ratios
  • Current Ratio: The company's current ratio deteriorated and stood at 1.3x during FY19, from 1.4x during FY18. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 13.1x during FY19, from 42.7x during FY18. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at 17.0% during FY19, from 20.7% during FY19. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company declined and down at 23.8% during FY19, from 27.4% during FY18. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company declined and down at 9.9% during FY19, from 11.8% during FY18. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-18* 12 Mar-19*
Current ratio x 1.4 1.3
Debtors’ Days Days 68 64
Interest coverage x 42.7 13.1
Debt to equity ratio x 0.0 0.0
Return on assets % 11.8 9.9
Return on equity % 20.7 17.0
Return on capital employed % 27.4 23.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



To see how AUROBINDO PHARMA has performed over the last 5 years, please visit here.

AUROBINDO PHARMA Share Price Performance

Over the last one year, AUROBINDO PHARMA share price has moved down from Rs 786.2 to Rs 454.5, registering a loss of Rs 331.7 or around 42.2%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,255.0 (up 0.5%). Over the last one year it has moved down from 14,441.9 to 13,255.0, a loss of 1,187 points (down 8.2%).

Overall, the S&P BSE SENSEX is up 15.1% over the year.

(To know more, check out historical annual results for AUROBINDO PHARMA and quarterly results for AUROBINDO PHARMA)

Equitymaster requests your view! Post a comment on "AUROBINDO PHARMA 2018-19 Annual Report Analysis". Click here!

  

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS